At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 231 enrolled
Drug / intervention
EDP-235 +1 moredrug
Likely dose
Not stated in record
Key inclusion· 2
- ✓Confirmed SARS-CoV-2 infection by positive test within 24 hours before randomization
- ✓COVID-19 symptom onset within 5 days prior to randomization with at least 2 signs/symptoms present, one of at least moderate severity
Key exclusion· 14
- ✕Prior SARS-CoV-2 infection or any COVID-19 vaccine dose within 90 days before enrollment
- ✕One or more conditions associated with high risk for severe COVID-19
- ✕History of hospitalization for medical treatment of COVID-19
- ✕Currently hospitalized or anticipated need for hospitalization
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of EDP-235 in Non-hospitalized Adults With Mild or Moderate COVID-19
In Brief
A Phase 2 clinical trial evaluating EDP-235 and Placebo for COVID-19. Completed, enrolled 231 participants across 23 sites in 2 countries.
Detailed Summary
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesRomania, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartNov 2022
First PostedNov 2022
Primary CompletionFeb 2023
Study CompletionJun 2023
TodayJul 2026
First PostedNov 15, 2022
Enrollment StartNov 10, 2022
Primary CompletionFeb 8, 2023
Study CompletionJun 29, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.6 years ago
Interventions
EDP-235drug
capsule
Placebodrug
capsule